Your browser doesn't support javascript.
loading
Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies.
Plaimauer, B; Kremer Hovinga, J A; Juno, C; Wolfsegger, M J; Skalicky, S; Schmidt, M; Grillberger, L; Hasslacher, M; Knöbl, P; Ehrlich, H; Scheiflinger, F.
Affiliation
  • Plaimauer B; Baxter Innovations GmbH, Wagramer Strasse, Vienna, Austria.
J Thromb Haemost ; 9(5): 936-44, 2011 May.
Article in En | MEDLINE | ID: mdl-21294825
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombotic Thrombocytopenic / Von Willebrand Factor / ADAM Proteins / Antibodies Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2011 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Purpura, Thrombotic Thrombocytopenic / Von Willebrand Factor / ADAM Proteins / Antibodies Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Thromb Haemost Journal subject: HEMATOLOGIA Year: 2011 Document type: Article Affiliation country: